相关实验视频

Updated: Jan 12, 2026

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

In Vivo Tracking of Edema Development and Microvascular Pathology in a Model of Experimental Cerebral Malaria Using Magnetic Resonance Imaging

Published on: June 8, 2017

在儿童脑疟疾患者队列中因特定原因死亡率

Hunter J Wynkoop¹, Ruth Bvalani-Kaunda², Karl B Seydel³

¹Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.

Malaria journal

|November 4, 2025

概括

在儿科大脑疟疾 (CM) 中,除了脑损伤之外,还有多种死亡原因. 了解这些不同的致命结果对于开发有效的辅助疗法和改善儿童生存率至关重要.

科学领域:

儿童传染病儿童传染病
疟疾研究疟疾研究
关键护理医学关键护理医学

背景情况:

儿科大脑疟疾 (CM) 仍然是全球儿童死亡的主要原因.
现有的CM干预试验尚未产生显著的生存益处.
多器官功能障碍综合征 (MODS) 是已知的CM并发症,但因特定原因的死亡率往往被忽视.

研究的目的:

调查儿童大脑疟疾死亡的直接原因.
分析临床参数与CM患者特定死亡原因之间的关系.
为CM的辅助疗法未来临床试验的设计提供信息.

主要方法:

从临床试验 (2018-2025) 中注册的CM儿童的数据的回顾性审查.
将死亡的直接原因分为七个预定义的组,对已故的参与者进行分类.
对临床数据的分析,包括入院昏迷得分,氧和和乳酸水平.

主要成果:

在393名儿童中,52名 (13%) 死亡;脑 (46%) 和带呼吸暂停的状态 (17%) 是最常见的神经病因.
非神经病因占死亡人数的37%,包括心力衰竭/休克 (13%),呼吸系统衰竭 (12%),功能衰竭 (6%),肝功能衰竭 (4%).
较低的入院昏迷得分与脑和肝衰竭有关;最低的氧和与呼吸衰竭有关;最高的乳酸与心脏/肝衰竭或其他原因有关.

结论:

儿童脑性疟疾中存在多种直接死亡原因,包括非神经器官衰竭.
死亡原因的异质性可能会掩盖临床试验中以大脑为重点的治疗方法的有效性.
未来的试验样本大小计算可能需要调整,以考虑到CM中死亡的各种原因.

关键词:

特定原因死亡率死亡的直接原因.疟疾:疟疾是一种疾病.

更多相关视频

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting

A Simple Protocol for Platelet-mediated Clumping of Plasmodium falciparum-infected Erythrocytes in a Resource Poor Setting

Published on: May 16, 2013

Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells

Selection of Plasmodium falciparum Parasites for Cytoadhesion to Human Brain Endothelial Cells

Published on: January 3, 2012

相关概念视频

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...